Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: Translational and back-translational research

Annals of the New York Academy of Sciences

Volumn 1343, Issue 1, 2015, Pages 27-36

  Strupp, Michael ^a   Zwergal, Andreas ^a   Feil, Katharina ^a   Bremova, Tatiana ^a   Brandt, Thomas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute unilateral vestibulopathy; Aminopyridines; Central vestibular disorders; Cerebellar ataxias; Downbeat nystagmus; Episodic ataxia type 2; M ni re's disease; Vestibular migraine; Vestibular paroxysmia

Indexed keywords

ACETAZOLAMIDE; ACETIC ACID DERIVATIVE; ACETYL DEXTRO LEUCINE; AMINOPYRIDINE DERIVATIVE; BETAHISTINE; CARBAMAZEPINE; CORTICOSTEROID; FAMPRIDINE; GENTAMICIN; METOPROLOL; OXCARBAZEPINE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; ATAXIA; BENIGN PAROXYSMAL POSITIONAL VERTIGO; CEREBELLAR ATAXIA; CEREBELLUM DISEASE; CLINICAL TRIAL (TOPIC); COCHLEA BLOOD FLOW; DRUG EFFICACY; EPISODIC ATAXIA TYPE 2; HUMAN; MENIERE DISEASE; MULTICENTER STUDY (TOPIC); NONHUMAN; NYSTAGMUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; TRANSLATIONAL RESEARCH; TREATMENT INDICATION; VERTIGO; VESTIBULAR DISORDER; VESTIBULAR MIGRAINE; VESTIBULAR NEURONITIS; VESTIBULAR PAROXYSMIA; ANIMAL; BODY EQUILIBRIUM; DRUG EFFECTS; NYSTAGMUS, PATHOLOGIC; PATHOPHYSIOLOGY; VESTIBULAR DISEASES; VESTIBULE;

AMINOPYRIDINES; ANIMALS; BETAHISTINE; HUMANS; NYSTAGMUS, PATHOLOGIC; POSTURAL BALANCE; TRANSLATIONAL MEDICAL RESEARCH; VESTIBULAR DISEASES; VESTIBULE, LABYRINTH;

EID: 84928187275     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12774     Document Type: Article

References (70)

1. Strupp, M., M.J. Thurtell, A.G. Shaikh, et al. 2011. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J. Neurol. 258: 1207-1222.
2. Huppert, D., M. Strupp, H. Muckter & T. Brandt . 2011. Which medication do I need to manage dizzy patients? Acta Otolaryngol. 131: 228-241.
3. Brandt, T., M. Dieterich & M. Strupp . 2013. Vertigo and Dizziness-Common Complaints. London: Springer.
4. Strupp, M., O. Kremmyda & T. Brandt . 2013. Pharmacotherapy of vestibular disorders and nystagmus. Semin. Neurol. 33: 286-296.
5. Zwergal, A., J. Schlichtiger, G. Xiong, et al. 2014. Sequential [18F]FDG μPET whole-brain imaging of central vestibular compensation: a model of deafferentation-induced brain plasticity. Brain Struct Funct. 1-12.
6. Beck, R., L. Gunther, G. Xiong, et al. 2014. The mixed blessing of treating symptoms in acute vestibular failure-evidence from a 4-aminopyridine experiment. Exp. Neurol. 261: 638-645.
7. Bisdorff, A., B.M. Von, T. Lempert & D.E. Newman-Toker . 2009. Classification of vestibular symptoms: towards an international classification of vestibular disorders. J. Vestib. Res. 19: 1-13.
8. Dutia, M.B. 2010. Mechanisms of vestibular compensation: recent advances. Curr. Opin. Otolaryngol Head Neck Surg. 18: 420-424.
9. Strupp, M., V.C. Zingler, V. Arbusow, et al. 2004. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N. Engl. J. Med. 351: 354-361.
10. Goudakos, J.K., K.D. Markou, V. Franco-Vidal, et al. 2010. Corticosteroids in the treatment of vestibular neuritis: a systematic review and meta-analysis. Otol. Neurotol. 31: 183-189.
11. Karlberg, M.L. & M. Magnusson . 2011. Treatment of acute vestibular neuronitis with glucocorticoids. Otol. Neurotol. 32: 1140-1143.
12. Goudakos, J.K., K.D. Markou, G. Psillas, et al. 2014. Corticosteroids and vestibular exercises in vestibular neuritis. Single-blind randomized clinical trial. JAMA Otolaryngol. Head Neck Surg. 140: 434-440.
13. Fishman, J.M., C. Burgess & A. Waddell . 2011. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane. Database. Syst. Rev. CD008607.
14. Wegner, I., P.P. VanBenthem, M.C. Aarts, et al. 2012. Insufficient evidence for the effect of corticosteroid treatment on recovery of vestibular neuritis. Otolaryngol. Head Neck Surg. 147: 826-831.
15. Günther, L., R. Beck, G. Xiong, H. Potschka, K. Jahn, P. Bartenstein, T. Brandt, M. Dutia, M. Dieterich, M. Strupp, C. la Fougère, A. Zwergal . 2015. N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus. PLoS One 10: e0120891
16. Strupp, M., V. Arbusow, K.P. Maag, et al. 1998. Vestibular exercises improve central vestibulospinal compensation after vestibular neuritis. Neurology 51: 838-844.
17. McDonnell, M.N. & S.L. Hillier . 2015. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst. Rev. 1:CD005397
18. Herdman, S.J. 2013. Vestibular rehabilitation. Curr. Opin. Neurol. 26: 96-101.
19. Lacour, M. 2013. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J. Vestib. Res. 23: 139-151.
20. Ihler, F., M. Bertlich, K. Sharaf, et al. 2012. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in Guinea pigs in vivo. PLoS. One 7: e39086.
21. Bertlich, M., F. Ihler, K. Sharaf, et al. 2014. Betahistine metabolites, Aminoethylpyridine, and Hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo. Int. J. Audiol. 53: 753-759.
22. Strupp, M., D. Hupert, C. Frenzel, et al. 2008. Long-term prophylactic treatment of attacks of vertigo in Meniere's disease-comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol. 128: 520-524.
23. Lezius, F., C. Adrion, U. Mansmann, et al. 2011. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniere's disease: a case series. Eur. Arch. Otorhinolaryngol. 268: 1237-1240.
24. Strupp, M., C. Cnyrim & T. Brandt . 2007. "Vertigo and dizziness: treatment of benign paroxysmal positioning vertigo, vestibular neuritis and Menère's disease." In Evidence-Based Neurology-Management of Neurological Disorders. L. Candelise, Ed.: 59-69. Oxford: Blackwell Publishing.
25. Nauta, J.J. 2014. Meta-analysis of clinical studies with betahistine in Meniere's disease and vestibular vertigo. Eur. Arch. Otorhinolaryngol. 271: 887-897.
26. Postema, R.J., C.M. Kingma, H.P. Wit, et al. 2008. Intratympanic gentamicin therapy for control of vertigo in unilateral Menire's disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol. 128: 876-880.
27. Stokroos, R. & H. Kingma . 2004. Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Meniere's disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol. 124: 172-175.
28. Pullens, B. & P.P. VanBenthem . 2011. Intratympanic gentamicin for Meniere's disease or syndrome. Cochrane Database Syst. Rev. CD008234.
29. Huon, L.K., T.Y. Fang & P.C. Wang . 2012. Outcomes of intratympanic gentamicin injection to treat Meniere's disease. Otol. Neurotol. 33: 706-714.
30. Colletti, V., M. Carner & L. Colletti . 2007. Auditory results after vestibular nerve section and intratympanic gentamicin for Meniere's disease. Otol. Neurotol. 28: 145-151.
31. Huppert, D., M. Strupp & T. Brandt . 2010. Long-term course of Meniere's disease revisited. Acta Otolaryngol. 130: 644-651.
32. Phillips, J.S. & B. Westerberg . 2011. Intratympanic steroids for Meniere's disease or syndrome. Cochrane Database Syst. Rev. CD008514.
33. Garduno-Anaya, M.A., T.H. Couthino De, R. Hinojosa-Gonzalez, et al. 2005. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol. Head Neck Surg. 133: 285-294.
34. Casani, A.P., P. Piaggi, N. Cerchiai, et al. 2012. Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol. Head Neck Surg. 146: 430-437.
35. Brandt, T. & M. Dieterich . 1994. VIIIth nerve vascular compression syndrome: vestibular paroxysmia. Baillieres Clin. Neurol. 3: 565-575.
36. Brandt, T. & M. Dieterich . 1994. Vestibular paroxysmia: vascular compression of the eighth nerve? Lancet 343: 798-799.
37. Strupp, M., S. VonStuckrad-Barre, T. Brandt & J.C. Tonn . 2013. Teaching NeuroImages: compression of the eighth cranial nerve causes vestibular paroxysmia. Neurology 80: e77.
38. Best, C., J. Gawehn, H.H. Kramer, et al. 2013. MRI and neurophysiology in vestibular paroxysmia: contradiction and correlation. J. Neurol. Neurosurg. Psychiatry 84: 1349-1356.
39. Hufner, K., D. Barresi, M. Glaser, et al. 2008. Vestibular paroxysmia: diagnostic features and medical treatment. Neurology 71: 1006-1014.
40. Lempert, T., J. Olesen, J. Furman, et al. 2012. Vestibular migraine: diagnostic criteria. J. Vestib. Res. 22: 167-172.
41. Obermann, M. & M. Strupp . 2014. Current treatment options in vestibular migraine. Front Neurol. 5: 257.
42. Maldonado, F.M., J.S. Birdi, G.J. Irving, et al. 2015. Pharmacological treatment for the prevention of vestibular migraine. Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD010600.
43. Ophoff, R.A., G.M. Terwindt, M.N. Vergouwe, et al. 1996. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87: 543-552.
44. Jen, J.C. 2008. Hereditary episodic ataxias. Ann. N. Y. Acad. Sci. 1142: 250-253.
45. Strupp, M., A. Zwergal & T. Brandt . 2007. Episodic ataxia type 2. Neurotherapeutics 4: 267-273.
46. Jen, J.C. & R.W. Baloh . 2009. Familial episodic ataxia: a model for migrainous vertigo. Ann. N. Y. Acad. Sci. 1164: 252-256.
47. Jen, J., G.W. Kim & R.W. Baloh . 2004. Clinical spectrum of episodic ataxia type 2. Neurology 62: 17-22.
48. Strupp, M., R. Kalla, M. Dichgans, et al. 2004. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62: 1623-1625.
49. Strupp, M., R. Kalla, J. Claassen, et al. 2011. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77: 269-275.
50. Alvina, K. & K. Khodakhah . 2010. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J. Neurosci. 30: 7258-7268.
51. Weisz, C.J., R.S. Raike, L.E. Soria-Jasso & E.J. Hess . 2005. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J. Neurosci. 25: 4141-4145.
52. Claassen, J., J. Teufel, R. Kalla, et al. 2013. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study. J. Neurol. 260: 668-669.
53. Strupp, M., O. Schuler, S. Krafczyk, et al. 2003. Treatment of downbeat nystagmus with 3, 4-diaminopyridine: a placebo-controlled study. Neurology 61: 165-170.
54. Tsunemi, T., K. Ishikawa, K. Tsukui, et al. 2010. The effect of 3, 4-diaminopyridine on the patients with hereditary pure cerebellar ataxia. J. Neurol. Sci. 292: 81-84.
55. Sprenger, A., E. Zils, H. Rambold, et al. 2005. Effect of 3, 4-diaminopyridine on the postural control in patients with downbeat nystagmus. Ann. N. Y. Acad. Sci. 1039: 395-403.
56. Helmchen, C., S. Gottschalk, T. Sander, et al. 2007. Beneficial effects of 3, 4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion. J. Neurol. 254: 1126-1128.
57. Kalla, R., S. Glasauer, U. Buttner, et al. 2007. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 130: 2441-2451.
58. Kalla, R., R. Spiegel, J. Claassen, et al. 2011. Comparison of 10-mg doses of 4-aminopyridine and 3, 4-diaminopyridine for the treatment of downbeat nystagmus. J. Neuroophthalmol. 31: 320-325.
59. Claassen, J., R. Spiegel, R. Kalla, et al. 2013. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus-effects on slowphase eye velocity, postural stability, locomotion and symptoms. J. Neurol. Neurosurg. Psychiatry 84: 1392-1399.
60. Claassen, J., K. Feil, S. Bardins, et al. 2013. Dalfampridine in patients with downbeat nystagmus-an observational study. J. Neurol. 260: 1992-1996.
61. Kremmyda, O., A. Zwergal, F.C. La, et al. 2013. 4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion. J. Neurol. 260: 321-323.
62. Ilg, W., A.J. Bastian, S. Boesch, et al. 2014. Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13: 248-268.
63. Feil, K., J. Claassen, S. Bardins, et al. 2013. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial. Neurology 81: 1152-1158.
64. Hille, B. 2001. Ionic Channels of Excitable Membranes. 3rd edition, Sinauer Associates, Sunderland, Mass.
65. Strupp, M., R. Kalla, S. Glasauer, et al. 2008. Aminopyridines for the treatment of cerebellar and ocular motor disorders. Prog. Brain Res. 171: 535-541.
66. Etzion, Y. & Y. Grossman . 2001. Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp. Brain Res. 139: 419-425.
67. Bense, S., C. Best, H.G. Buchholz, et al. 2006. 18F-fluorodeoxyglucose hypometabolism in cerebellar tonsil and flocculus in downbeat nystagmus. Neuroreport 17: 599-603.
68. Hourez, R., L. Servais, D. Orduz, et al. 2011. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 31: 11795-11807.
69. Schniepp, R., M. Wuehr, M. Neuhaeusser, et al. 2012. 4-aminopyridine and cerebellar gait: a retrospective case series. J. Neurol. 259: 2491-2493.
70. Strupp, M., J. Teufel, M. Habs, et al. 2013. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J. Neurol. 260: 2556-2561.